BiotechTube

Trastuzumab deruxtecan + Standard-of-Care

Phase 2Active
1 views this week 0 watching💤 Quiet
Interest: 39/100
39
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

HER2-positive Early Breast Cancer

Conditions

HER2-positive Early Breast Cancer

Trial Timeline

Feb 5, 2024 → Jun 1, 2029

NCT ID
NCT05704829

About Trastuzumab deruxtecan + Standard-of-Care

Trastuzumab deruxtecan + Standard-of-Care is a phase 2 stage product being developed by AstraZeneca for HER2-positive Early Breast Cancer. The current trial status is active. This product is registered under clinical trial identifier NCT05704829. Target conditions include HER2-positive Early Breast Cancer.

What happened to similar drugs?

0 of 15 similar drugs in HER2-positive Early Breast Cancer were approved

Approved (0) Terminated (0) Active (15)
🔄TrastuzumabCelltrionPhase 3
🔄Trastuzumab + Pertuzumab + Docetaxel + Paclitaxel + Nab-paclitaxel + Vinorelbine + Eribulin + Capecitabine + GemcitabineChugai PharmaceuticalPhase 3
🔄Trastuzumab deruxtecan + Placebo + Taxane + Pertuzumab + TrastuzumabDaiichi SankyoPhase 3
🔄DS-8201a + T-DM1Daiichi SankyoPhase 3
🔄SHR-A1811 Injection + SHR-A1811 Injection ； Pertuzumab Injection + Trastuzumab Injection；Pertuzumab Injection ； Docetaxel InjectionJiangsu Hengrui MedicinePhase 3
🔄SHR-A1811 for Injection + Docetaxel injection + Trastuzumab Injection + Carboplatin for Injection + Pertuzumab InjectionJiangsu Hengrui MedicinePhase 3
🔄Pyrotinib + Placebo Oral Tablet + Trastuzumab + DocetaxelJiangsu Hengrui MedicinePhase 3

Hype Score Breakdown

Clinical
12
Activity
12
Company
15
Novelty
0
Community
0

Clinical Trials (1)

NCT IDPhaseStatus
NCT05704829Phase 2Active

Competing Products

20 competing products in HER2-positive Early Breast Cancer

See all competitors
ProductCompanyStageHype Score
ALT-P7 (HM2-MMAE)AlteogenPhase 1
29
CT-0508 + PembrolizumabCarisma TherapeuticsPhase 1
23
CT-0525Carisma TherapeuticsPhase 1
23
TrastuzumabCelltrionPhase 3
40
Trastuzumab + Pertuzumab + Docetaxel + Paclitaxel + Nab-paclitaxel + Vinorelbine + Eribulin + Capecitabine + GemcitabineChugai PharmaceuticalPhase 3
40
YH32367YuhanPhase 1/2
39
Trastuzumab deruxtecanDaiichi SankyoPre-clinical
33
Trastuzumab deruxtecanDaiichi SankyoPre-clinical
26
Trastuzumab deruxtecanDaiichi SankyoPre-clinical
33
Trastuzumab deruxtecan (T-DXd)Daiichi SankyoPre-clinical
33
Trastuzumab deruxtecanDaiichi SankyoPhase 2
42
Trastuzumab deruxtecan + Placebo + Taxane + Pertuzumab + TrastuzumabDaiichi SankyoPhase 3
44
DS-8201a + T-DM1Daiichi SankyoPhase 3
44
Pertuzumab + Trastuzumab + eribulinEisaiPhase 2
27
Tucatinib 150 MG + Trastuzumab + CapecitabineBioconPhase 2
42
SHR-A1811 Injection + SHR-A1811 Injection ； Pertuzumab Injection + Trastuzumab Injection；Pertuzumab Injection ； Docetaxel InjectionJiangsu Hengrui MedicinePhase 3
44
PyrotinibJiangsu Hengrui MedicinePre-clinical
22
SHR-A1811 for Injection + Docetaxel injection + Trastuzumab Injection + Carboplatin for Injection + Pertuzumab InjectionJiangsu Hengrui MedicinePhase 3
47
Pyrotinib + Placebo Oral Tablet + Trastuzumab + DocetaxelJiangsu Hengrui MedicinePhase 3
40
SHR-A1811 + Ramucirumab / Paclitaxel/ Docetaxel/ IrinotecanJiangsu Hengrui MedicinePhase 3
47